166 related articles for article (PubMed ID: 9376978)
1. Disease-modifying anti-rheumatic drugs. Cyclosporin.
Chaudhuri K; Torley H; Madhok R
Br J Rheumatol; 1997 Sep; 36(9):1016-21. PubMed ID: 9376978
[No Abstract] [Full Text] [Related]
2. Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis: an update on mechanisms of action.
Danning CL; Boumpas DT
Clin Exp Rheumatol; 1998; 16(5):595-604. PubMed ID: 9779311
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine dosing for RA.
Redford TW; Small RE
Am Pharm; 1995 Mar; NS35(3):5. PubMed ID: 8533729
[No Abstract] [Full Text] [Related]
4. Clinical use of cyclosporin in rheumatoid arthritis.
Richardson C; Emery P
Drugs; 1995; 50 Suppl 1():26-36. PubMed ID: 8714796
[TBL] [Abstract][Full Text] [Related]
5. Chronic cyclosporine nephrotoxicity in rheumatoid arthritis.
Pei Y
J Rheumatol; 1996 Jan; 23(1):4-5. PubMed ID: 8838500
[No Abstract] [Full Text] [Related]
6. Inhibitory effect of enzyme therapy and combination therapy with cyclosporin A on collagen-induced arthritis.
Rovenská E; Svík K; Stancíková M; Rovenský J
Clin Exp Rheumatol; 2001; 19(3):303-9. PubMed ID: 11407084
[TBL] [Abstract][Full Text] [Related]
7. Effects of cyclosporin on joint damage in rheumatoid arthritis. The Italian Rheumatologists Study Group on Rheumatoid Arthritis.
Ferraccioli GF; Bambara LM; Ferraris M; Perpignano G; Cattaneo R; Porzio F; Accardo S; Mattara L; Zoppini A; Benucci M; Ostuni PA; Pasero G
Clin Exp Rheumatol; 1997; 15 Suppl 17():S83-9. PubMed ID: 9266138
[TBL] [Abstract][Full Text] [Related]
8. Rheumatology. Part 2: The role of medication.
Byrne J
Prof Nurse; 1999 Feb; 14(5):353-8. PubMed ID: 10205553
[TBL] [Abstract][Full Text] [Related]
9. [Disease modifying antirheumatic drugs].
Luong Ba K; Gabay C
Rev Med Suisse; 2014 Mar; 10(421):595-6, 598, 600-2. PubMed ID: 24701712
[TBL] [Abstract][Full Text] [Related]
10. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
Choy E
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
[TBL] [Abstract][Full Text] [Related]
12. How do second-line agents work?
Choy E; Kingsley G
Br Med Bull; 1995 Apr; 51(2):472-92. PubMed ID: 7552077
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Suzuki Y; Wakabayashi T; Saito E; Suwa A
Clin Calcium; 2007 Apr; 17(4):546-52. PubMed ID: 17404484
[TBL] [Abstract][Full Text] [Related]
14. Biological disease modifying anti-rheumatic drugs.
Cranwell-Bruce LA
Medsurg Nurs; 2011; 20(3):147-50. PubMed ID: 21786492
[No Abstract] [Full Text] [Related]
15. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis.
Garrood T; Scott DL
BioDrugs; 2001; 15(8):543-61. PubMed ID: 11543695
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid arthritis therapy: advances from bench to bedside.
Choi SI; Brahn E
Autoimmunity; 2010 Nov; 43(7):478-92. PubMed ID: 20429843
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporin A and FK-506 inhibit development of superantigen-potentiated collagen-induced arthritis in mice.
Takaoka Y; Nagai H; Tanahashi M; Kawada K
Gen Pharmacol; 1998 May; 30(5):777-82. PubMed ID: 9559334
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin can be used in early rheumatoid arthritis.
Dawson JK; Roychowdhury B; Tunn EJ
BMJ; 1997 Jun; 314(7097):1828. PubMed ID: 9224095
[No Abstract] [Full Text] [Related]
19. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
[TBL] [Abstract][Full Text] [Related]
20. Putting new disease-modifying antirheumatic drugs into perspective.
Saseen JJ
Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
[No Abstract] [Full Text] [Related]
[Next] [New Search]
